Covis Pharma taps Verify ahead of the extended DSCSA mandate

By Melissa Fassbender

- Last updated on GMT

The FDA has extended its serialization deadline until November 2018. (Image: iStock/Marko Rupena)
The FDA has extended its serialization deadline until November 2018. (Image: iStock/Marko Rupena)
The Switzerland-based biotech company has selected Verify Brand as its serialization software provider to meet the FDA’s – recently extended – DSCSA deadline.

As Outsourcing-Pharma.com previously reported​, the US Food and Drug Administration (FDA) recently published a draft guidance​ in which it explained enforcement of the Drug Supply Chain Security Act (DSCSA) will be extended until November 2018.

According Verify, a cross-industry, serialization and authentication solution company, its SWIFT serialization implementation process will enable Covis Pharma to implement necessary DSCSA compliance components.

Even though the FDA recently extended the DSCSA product identification mandate, we’re seeing many pharma manufacturers like Covis move their serialization projects forward for a couple of reasons​,” Michael Howe, CEO, Verify Brand told Outsourcing-Pharma.com.

First, pharma companies must still comply with the parts of the DSCSA that take effect in November 2017​,” he said.

Additionally, the FDA acknowledges that​ “stakeholders have described challenges with implementation of product identifier requirements due to a limited number of vendors that that have the expertise to provide solutions related to information technology systems for data management​.”

This puts pharma companies at risk of missing FDA deadlines if they choose a provider with limited experience and capabilities​,” said Howe.

Covis has already integrated the Verify Platform’s standards-based EPCIS software throughout much of its supply chain partner network. 

Related news

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Follow us

Products

View more

Webinars